Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine

  1. Francisco Belda
  2. Oscar Mora
  3. Monica Lopez Martinez
  4. Nerea Torres
  5. Ana Vivanco
  6. Rebecca Christie
  7. Michael Crowley

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.vaccine.2022.04.006
  2. ScreenIT

    SciScore for 10.1101/2021.06.20.21258152: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: The samples were collected with informed consent under an approved IRB protocol ([1149706-4] Diagnostic QC and Pre-Clinical Sample Collection Project: Ballad Health System Institutional Review Board, Johnson City, TN, USA) and in compliance with all applicable regulatory guidelines.
    IRB: The samples were collected with informed consent under an approved IRB protocol ([1149706-4] Diagnostic QC and Pre-Clinical Sample Collection Project: Ballad Health System Institutional Review Board, Johnson City, TN, USA) and in compliance with all applicable regulatory guidelines.
    Sex as a biological variableThere were 5 male and 10 female subjects in this group.
    RandomizationThis vaccine has been proven to be highly efficacious in a phase 3 randomized, observer-blinded, placebo-controlled clinical trial – preventing 94% of Covid-19 illness in treated subjects compared to the placebo group.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Limitations of this study include the number of subjects studied and a racial distribution that is not a representative of the total population. Another limitation is that the detection assays used are not neutralizing antibodies assays that will detect the actual amount of viral blocking antibodies. Furthermore, it would be interesting to determine the presence of specific antibodies against different antigenic parts of the virus than S1 and S2 spike proteins (e.g. nucleocapside protein), in the group of post-vaccination samples from COVID-19 convalescent subjects. In conclusion, the data presented here show that these seroconversion panels demonstrate the appearance of anti-SARS-CoV-2 IgG after vaccination. The data also show that individual subjects with previous COVID-19 show an enhanced response to the first vaccination. It was also observed that weaker responses to the first injection – observed in four elderly subjects (over 70 years old) and three younger subjects (55-70 years old) – were overcome by the second injection. All subjects in these seroconversion panels generated anti-SARS-CoV-2 IgG in response to the mRNA-1273 SARS-CoV-2 vaccine. These data show that these conversion panels could be useful tools for the development and comparison of serological tests for COVID-19 and quality control during their manufacture.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.06.20.21258152 on medRxiv